NAD+ Precursors & Mitochondrial Support

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell that is essential for energy metabolism, DNA repair, and cellular signaling. NAD+ levels decline approximately 50% between ages 40 and 60. This decline directly impacts mitochondrial function (Root Cause 3) because NAD+ is required for the electron transport chain to produce ATP. It also impairs the activity of sirtuins, a family of enzymes that regulate DNA repair, inflammation, and metabolic homeostasis. Restoring NAD+ levels is considered a cornerstone intervention in longevity medicine.

The two primary NAD+ precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are converted to NAD+ through enzymatic pathways in the body. NMN is one step closer to NAD+ in the biosynthetic pathway, requiring only one enzymatic conversion versus two for NR. Typical dosing for NMN is 500-1000mg orally per day; for NR, 300-600mg daily. Some practitioners combine oral NAD+ precursors with intravenous NAD+ infusions (250-750mg) for acute restoration, particularly in cases of severe mitochondrial dysfunction, chronic fatigue, or neurodegeneration.

Mitochondrial peptides complement NAD+ precursor supplementation by directly supporting the structural and functional integrity of mitochondria. SS-31 (elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, preserving cristae structure and ETC complex efficiency. Humanin, a mitochondrial-derived peptide, protects against oxidative stress and apoptosis. MOTS-c optimizes mitochondrial gene expression and metabolic function. A comprehensive longevity protocol targeting Root Cause 3 might combine an NAD+ precursor (NMN or NR) with a mitochondrial peptide (SS-31 or MOTS-c) and an electron transport chain supporter (Methylene Blue) for multi-level mitochondrial restoration.